Home>

Products

Submit Request Quote
 * Denotes Required Field.
Name:
 *
Company Name:
Phone:
Email:
 *
Message:
Request Quote
 
Out Of Stock image

Is currently out of stock, however if you enter your email address we will notify you when it comes back into stock!

Continue shopping Get Notified

Anti-CD20 [2B8R1F8]-Afucosylated

Anti-CD20 [2B8R1F8]-Afucosylated
Product Type: Therapeutics (In Vivo)
Format: Anti-CD20, 2B8R1F8, rhesusized variable region, rhesus IgG1 Fc, afucosylated
Clone ID: 2B8
RRID: AB_2819341
Common Names: Anti-CD20 [2B8R1F8]-Afucosylated | Afucosylated Depleting anti-CD20 (rhesus recombinant) | PR-8288 | NHP21 | aCD20_2B8_rz_G1k_AF_mamu
Target: CD20
Reactivity: Rhesus Macaque (Macaca mulatta) Human (Homo sapiens)
Applications: in vivo; depletion
Description:

2B8R1F8: Rhesus recombinant, CDR-grafted, afucosylated IgG1-kappa anti-CD20 antibody. Derived from rituximab.
Modifications: afucosylated
Restrictions: No
Sponsor: ORIP
How to cite (Methods): The Anti-CD20 [2B8R1F8]-Afucosylated antibody was engineered and produced by the Nonhuman Primate Reagent Resource (NIH Nonhuman Primate Reagent Resource Cat#PR-8288,RRID:AB_2819341).
How to cite (Acknowledgments): The Anti-CD20 [2B8R1F8]-Afucosylated antibody used in this study was provided by the NIH Nonhuman Primate Reagent Resource (ORIP P40 OD028116).

Reagent cost, which is the actual cost of production, is recovered for some reagents. Please inquire if you have questions about reagent cost recovery. Purchase order or credit card is NOW REQUIRED for cost-recovered reagents.

You are not authorized to purchase this product. Please ensure you are logged into your account.

CAN'T FIND EXACTLY WHAT YOUR RESEARCH REQUIRES?

Request a Reagent:

Would you like to see an NHP-specific antibody developed through the program? Suggest a new reagent that would benefit the NHP community.

REQUEST A REAGENT

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).

Copyright © 2004-2024